




RealRate

PHARMACEUTICAL 2026

Sonoma Pharmaceuticals Inc
Rank 113 of 178



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 44% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	12,648
Cost of Goods Sold	8,823
Intangible Assets	0
Liabilities, Current	4,096
Liabilities, Non-Current	27
Other Assets	820
Other Compr. Net Income	-1,653
Other Expenses	550
Other Liabilities	5,159
Other Net Income	803
Other Revenues	14,288
Property and Equipment	225
Research and Development	1,814
Selling, General and Administrative Expense	7,361

Output Variable	Value in 1000 USD
Assets	13,693
Liabilities	9,282
Expenses	18,548
Revenues	14,288
Stockholders Equity	4,411
Net Income	-3,457
Comprehensive Net Income	-4,284
BaseVar	29,134
ECR before Limited Liability	46%
Economic Capital Ratio	185%